Catalent Expert Speaks on the Future of Biologics at the 2011 BIONJ Manufacturing Summit
Somerset, NJ, March 9, 2011 — Cornell Stamoran, Vice President of Corporate Development and Strategy for Catalent Pharma Solutions, will speak on “The Future of Therapeutic Biologics” at the BioNJ Manufacturing Summit on March 10, at the Hilton East Brunswick in East Brunswick, NJ.
Mr. Stamoran will share expert insights on therapeutic biologics and how to reverse engineer successful product supply. He will also review the rapidly evolving clinical and commercial factors that influence biologics development decision-making, specifically highlighting implications for supply chain planning, funding and operating models. The presentation will begin at 8:30 a.m. on Thursday, March 10.
With more than 20 years of experience in the pharmaceutical and healthcare industries, Mr. Stamoran leads Catalent’s market intelligence and strategy functions, as well as supporting its global M&A activities. Additionally, he serves as an investor relations officer.
Catalent’s biologics offerings include the proprietary GPEx® gene expression technology which is faster, more reliable and more flexible than traditional methods of gene insertion and can ensure that genetically stable cell lines are produced 100% of the time. Catalent also provides a full range of services including analytical and development services, sterile fill finish capabilities, cold chain handling, kitting, packaging and regulatory consulting.
For more information about Catalent or to schedule an interview with Mr. Stamoran, please contact Patricia McGee at email@example.com .
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,000 people at 28 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ.